Rocket Pharmaceuticals
RCKT
164 hedge funds and large institutions have $1.1B invested in Rocket Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 64 increasing their positions, 40 reducing their positions, and 14 closing their positions.
1,036% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $902K
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
60% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 40
23% more capital invested
Capital invested by funds: $892M → $1.1B (+$210M)
12% more funds holding
Funds holding: 147 → 164 (+17)
6.17% more ownership
Funds ownership: 98.41% → 104.58% (+6.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$13.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$13.4M |
| 3 |
Goldman Sachs
New York
|
+$8.33M |
| 4 |
BlackRock
New York
|
+$7.62M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$7.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$10.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$10.4M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.82M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.57M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.31M |
RCKT Hedge Fund Activity: Q3 2022 in Review
164 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2022, worth a combined $1.1B — up 23% from $892M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RCKT positions and 14 closed out — a net gain of 17 holders — while 64 added to existing stakes and 40 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $13.6M. The largest seller was Westfield Capital Management, cutting an estimated $10.9M.
- 164 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2022, up from 147 in Q2 2022.
- Funds reported $1.1B of Rocket Pharmaceuticals stock for Q3 2022, up 23% quarter-over-quarter.
- 31 funds opened new Rocket Pharmaceuticals positions in Q3 2022 and 14 closed out, a net change of +17 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2022 was Deerfield Management, an estimated $13.6M added.
- The largest Rocket Pharmaceuticals seller in Q3 2022 was Westfield Capital Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q3 2022.